KOSDAQ large cap
디앤디파마텍
A drug-development biotech focused on metabolic and obesity therapeutics, centered on oral GLP-1 peptide candidates. KOSDAQ large-cap constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
347850.KQ Updated Jul 11, 2026 2 AI consumers· 1 recurring
Annual return · 2026-07-10'25+551.7%YTD-10.8%
Money in ▸·
디앤디파마텍
▸ Money out·
Financials & Segments
- Segments · Drug development (GLP-1 class) · Licensing-out
Revenue from
No refined links yet.
Pays to
No refined links yet.